Global Experts, Local Presence: Strengthening Europe’s Advanced Therapy Supply Chain 

The development and commercialization of Advanced Therapy Medicinal Products (ATMPs) in Europe require a highly coordinated supply chain. From temperature-controlled logistics and biostorage to regulatory compliance, every stage of the ATMP lifecycle depends on precision, reliability, and risk mitigation. Yet, many developers encounter logistical bottlenecks, regulatory complexity, and storage challenges that can delay progress and add unnecessary risk. 

At Cryoport Systems, we recognize these challenges and have built a specialized, integrated supply chain platform designed to meet the unique demands of ATMP development. Our growing presence in Europe provides direct, local access to the critical infrastructure needed to support clinical trials, scale manufacturing, and navigate regulatory requirements without compromising quality or compliance. 

 

The Challenges of ATMP Supply Chain Management 

ATMPs, including cell and gene therapies (CGTs), require stringent environmental controls and end-to-end traceability. Developers face several key obstacles when scaling from research to commercialization: 

  • Maintaining Product Integrity: The viability of cell-based therapies is highly sensitive to temperature fluctuations, making temperature-controlled supply chain management solutions a critical factor in supporting scalability. 
  • Regulatory Complexity: Moving ATMPs across borders requires expertise in European Medicines Agency (EMA) regulations, import/export controls, and Qualified Person (QP) oversight. 
  • Limited Infrastructure: Biopharma companies need secure, GMP-compliant BioServices and biostorage that align with their manufacturing and distribution strategies. 

Without a robust, integrated supply chain, developers risk delays, increased costs, and potential loss of irreplaceable therapeutic materials. 

 

Building a Resilient ATMP Supply Chain in Europe 

To address these challenges, Cryoport Systems has established a network of specialized supply chain centers across Europe, each designed to support different aspects of ATMP development: 

  • Stevenage, UK – A Gateway to Europe
    Situated within the UK’s leading bioscience cluster, our Global Supply Chain Hub provides temperature-controlled logistics, near real-time monitoring, and local regulatory support to streamline ATMP distribution across Europe. With the inherent complexity of cross-border shipments, our Stevenage hub ensures that UK-based developers can efficiently launch and scale clinical trials in the EU. 
  • Amsterdam, Netherlands – Global Logistics Center
    As a central access point for temperature-controlled packaging and international transportation, our Amsterdam facility provides temperature-controlled shipping solutions, Cryoshuttle® local pickup and delivery, and robust customs clearance support, reducing risk and transit time for high-value biologics. 
  • Clermont-Ferrand & Pont-du-Château, France – Integrated BioServices Centers
    ATMP development demands more than logistics; biostorage, centralized lab services, and clinical sample management are essential. Our French BioServices Centers provide secure GMP biorepository storage, patient sample processing, and regulatory-compliant packaging and labeling services to support both clinical and commercial programs, alongside Qualified Person (QP) support for streamlined scalability into Europe. 
  • Villers-le-Bouillet, Belgium – Cryopreservation Center
    The viability of cell-based therapies depends on standardized, high-quality cryopreservation. Our new IntegriCell™ Cryopreservation Center provides ATMP developers with validated cryopreservation processes and seamless integration with our logistics platform, ensuring the highest level of quality control from collection through final delivery. 
  • Coming Soon: Paris, France – Global Supply Chain Center
    In late 2025, we will expand our end-to-end supply chain solutions with a new Global Supply Chain Center in Paris. This facility will enhance our ATMP support across Europe, providing integrated storage, kit production, distribution, and risk-mitigating supply chain solutions to support clinical trials and commercial operations at scale.   
Strengthening the Future of ATMPs in Europe 

As ATMP development accelerates, so does the need for precision, compliance, and supply chain resilience. A fragmented or unreliable logistics and supply chain strategy can derail even the most promising therapies. By investing in specialized infrastructure, advanced tracking technologies, and expert regulatory support, Cryoport Systems is ensuring that developers have the certainty and control needed to bring life-saving therapies to patients across Europe and beyond. 

For ATMP sponsors, CDMOs, and clinical teams looking to strengthen their European supply chain, the right partner makes all the difference. Whether you’re navigating early-stage clinical trials or scaling up for commercial distribution, Cryoport Systems provides the expertise, infrastructure, and risk mitigation strategies needed to protect your critical materials at every step.